1 |
EDNRA
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer | D01227
D01227
|
Bosentan
| 11件: 13 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 |
2 |
EDNRA
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer | D07077
D07077
|
Ambrisentan
| 7件: 51 51, 84, 85, 86, 88, 210, 211 |
3 |
EDNRA
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer | D07171
D07171
|
Sitaxentan
| 1件: 86 86 |
4 |
EDNRA
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer | D07538
D07538
|
Bosentan
| 11件: 13 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 |
5 |
EDNRA
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer | D07741
D07741
|
Zibotentan
| 1件: 51 51 |
6 |
EDNRA
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer | D10135
D10135
|
Macitentan
| 5件: 51 51, 85, 86, 88, 210 |
7 |
EDNRA
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer | D11776
D11776
|
Sparsentan
| 3件: 66 66, 218, 222 |
8 |
EDNRB
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer | D01227
D01227
|
Bosentan
| 11件: 13 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 |
9 |
EDNRB
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer | D07538
D07538
|
Bosentan
| 11件: 13 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 |
10 |
EDNRB
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer | D10135
D10135
|
Macitentan
| 5件: 51 51, 85, 86, 88, 210 |
11 |
EGFR
| 48件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Adherens junction, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Bladder cancer, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D01977
D01977
|
Gefitinib
| 1件: 75 75 |
12 |
EGFR
| 48件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Adherens junction, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Bladder cancer, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D03455
D03455
|
Cetuximab
| 5件: 34 34, 51, 86, 89, 331 |
13 |
EGFR
| 48件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Adherens junction, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Bladder cancer, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D04023
D04023
|
Erlotinib
| 1件: 94 94 |
14 |
EGFR
| 48件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Adherens junction, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Bladder cancer, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D04024
D04024
|
Lapatinib
| 3件: 34 34, 74, 75 |
15 |
EGFR
| 48件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Adherens junction, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Bladder cancer, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D07907
D07907
|
Erlotinib
| 1件: 94 94 |
16 |
EGFR
| 48件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Adherens junction, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Bladder cancer, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08108
D08108
|
Lapatinib
| 3件: 34 34, 74, 75 |
17 |
EGFR
| 48件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Adherens junction, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Bladder cancer, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11251
D11251
|
Icotinib
| 1件: 34 34 |
18 |
EGFR
| 48件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Adherens junction, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Bladder cancer, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11772
D11772
|
Tesevatinib
| 1件: 67 67 |
19 |
EPHA2
| 5件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, PI3K-Akt signaling pathway, Axon guidance | D03658
D03658
|
Dasatinib
| 2件: 51 51, 85 |
20 |
EPHA2
| 5件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, PI3K-Akt signaling pathway, Axon guidance | D06414
D06414
|
Dasatinib
| 2件: 51 51, 85 |
21 |
ELANE
| 3件: Neutrophil extracellular trap formation Neutrophil extracellular trap formation, Transcriptional misregulation in cancer, Systemic lupus erythematosus | D03788
D03788
|
Sivelestat
| 3件: 13 13, 85, 96 |
22 |
EPHB4
| 1件: Axon guidance Axon guidance | D11772
D11772
|
Tesevatinib
| 1件: 67 67 |
23 |
EPOR
| 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D03231
D03231
|
Erythropoietin
| 10件: 2 2, 6, 13, 18, 22, 46, 47, 70, 95, 96 |
24 |
EPOR
| 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D09946
D09946
|
Peginesatide
| 1件: 283 283 |
25 |
ERBB2
| 22件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Platinum drug resistance, MAPK signaling pathway, ErbB signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Adherens junction, Tight junction, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Endometrial cancer, Prostate cancer, Bladder cancer, Non-small cell lung cancer, Breast cancer, Gastric cancer, Central carbon metabolism in cancer | D04024
D04024
|
Lapatinib
| 3件: 34 34, 74, 75 |
26 |
ERBB2
| 22件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Platinum drug resistance, MAPK signaling pathway, ErbB signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Adherens junction, Tight junction, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Endometrial cancer, Prostate cancer, Bladder cancer, Non-small cell lung cancer, Breast cancer, Gastric cancer, Central carbon metabolism in cancer | D08108
D08108
|
Lapatinib
| 3件: 34 34, 74, 75 |
27 |
ERBB2
| 22件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Platinum drug resistance, MAPK signaling pathway, ErbB signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Adherens junction, Tight junction, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Endometrial cancer, Prostate cancer, Bladder cancer, Non-small cell lung cancer, Breast cancer, Gastric cancer, Central carbon metabolism in cancer | D11772
D11772
|
Tesevatinib
| 1件: 67 67 |
28 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D00105
D00105
|
Estradiol
| 7件: 13 13, 46, 49, 65, 76, 226, 299 |
29 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D00185
D00185
|
Estriol
| 2件: 13 13, 227 |
30 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D00289
D00289
|
Danazol
| 5件: 60 60, 63, 64, 65, 285 |
31 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D00554
D00554
|
Ethinylestradiol
| 4件: 13 13, 46, 49, 299 |
32 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D00575
D00575
|
Mestranol
| 2件: 46 46, 49 |
33 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D00962
D00962
|
Clomifene
| 1件: 74 74 |
34 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D00966
D00966
|
Tamoxifen
| 4件: 2 2, 86, 113, 227 |
35 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D01161
D01161
|
Fulvestrant
| 2件: 49 49, 86 |
36 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D01413
D01413
|
Estradiol
| 7件: 13 13, 46, 49, 65, 76, 226, 299 |
37 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D01413
D01413
|
Estradiol valerate
| 1件: 65 65 |
38 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D01617
D01617
|
Estradiol
| 7件: 13 13, 46, 49, 65, 76, 226, 299 |
39 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D01953
D01953
|
Estradiol
| 7件: 13 13, 46, 49, 65, 76, 226, 299 |
40 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D01986
D01986
|
Estriol
| 2件: 13 13, 227 |
41 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D02217
D02217
|
Raloxifene
| 1件: 46 46 |
42 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D02367
D02367
|
Desogestrel
| 1件: 230 230 |
43 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D04061
D04061
|
Estradiol
| 7件: 13 13, 46, 49, 65, 76, 226, 299 |
44 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D04063
D04063
|
Estradiol
| 7件: 13 13, 46, 49, 65, 76, 226, 299 |
45 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D04064
D04064
|
Estradiol
| 7件: 13 13, 46, 49, 65, 76, 226, 299 |
46 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D04065
D04065
|
Estradiol
| 7件: 13 13, 46, 49, 65, 76, 226, 299 |
47 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D07726
D07726
|
Clomifene
| 1件: 74 74 |
48 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D08409
D08409
|
Prasterone
| 6件: 49 49, 53, 83, 86, 96, 113 |
49 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D08465
D08465
|
Raloxifene
| 1件: 46 46 |
50 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D08559
D08559
|
Tamoxifen
| 4件: 2 2, 86, 113, 227 |
51 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D11513
D11513
|
Estetrol
| 1件: 53 53 |
52 |
ESR1
| 9件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D11514
D11514
|
Estetrol
| 1件: 53 53 |
53 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D00105
D00105
|
Estradiol
| 7件: 13 13, 46, 49, 65, 76, 226, 299 |
54 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D00185
D00185
|
Estriol
| 2件: 13 13, 227 |
55 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D00575
D00575
|
Mestranol
| 2件: 46 46, 49 |
56 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D00962
D00962
|
Clomifene
| 1件: 74 74 |
57 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D00966
D00966
|
Tamoxifen
| 4件: 2 2, 86, 113, 227 |
58 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D01161
D01161
|
Fulvestrant
| 2件: 49 49, 86 |
59 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D01413
D01413
|
Estradiol
| 7件: 13 13, 46, 49, 65, 76, 226, 299 |
60 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D01413
D01413
|
Estradiol valerate
| 1件: 65 65 |
61 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D01617
D01617
|
Estradiol
| 7件: 13 13, 46, 49, 65, 76, 226, 299 |
62 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D01953
D01953
|
Estradiol
| 7件: 13 13, 46, 49, 65, 76, 226, 299 |
63 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D01986
D01986
|
Estriol
| 2件: 13 13, 227 |
64 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D02217
D02217
|
Raloxifene
| 1件: 46 46 |
65 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D04061
D04061
|
Estradiol
| 7件: 13 13, 46, 49, 65, 76, 226, 299 |
66 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D04063
D04063
|
Estradiol
| 7件: 13 13, 46, 49, 65, 76, 226, 299 |
67 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D04064
D04064
|
Estradiol
| 7件: 13 13, 46, 49, 65, 76, 226, 299 |
68 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D04065
D04065
|
Estradiol
| 7件: 13 13, 46, 49, 65, 76, 226, 299 |
69 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D07726
D07726
|
Clomifene
| 1件: 74 74 |
70 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D08409
D08409
|
Prasterone
| 6件: 49 49, 53, 83, 86, 96, 113 |
71 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D08465
D08465
|
Raloxifene
| 1件: 46 46 |
72 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D08559
D08559
|
Tamoxifen
| 4件: 2 2, 86, 113, 227 |
73 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D11513
D11513
|
Estetrol
| 1件: 53 53 |
74 |
ESR2
| 7件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D11514
D11514
|
Estetrol
| 1件: 53 53 |
75 |
ENPP2
| 2件: Ether lipid metabolism Ether lipid metabolism, Metabolic pathways | D11844
D11844
|
Ziritaxestat
| 2件: 51 51, 85 |